Biased signalling and proteinase-activated receptors (PARs): Targeting inflammatory disease

British Journal of Pharmacology

Volumn 171, Issue 5, 2014, Pages 1180-1194

  Hollenberg, M D ^a   Mihara, K ^a   Polley, D ^a   Suen, J Y ^b   Han, A ^b   Fairlie, D P ^b   Ramachandran, R ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

activated protein C; biased signalling; GPCR; protease; proteinase activated receptor; thrombin

Indexed keywords

COCKROACH ALLERGEN PROTEINASE E1; GB 88; LEUKOCYTE ELASTASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PEPDUCIN; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 3 ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR 4; PROTEINASE ACTIVATED RECEPTOR 4 ANTAGONIST; THROMBIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME CONFORMATION; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; NONHUMAN; PLASTICITY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION;

ACTIVATED PROTEIN-C; BIASED SIGNALLING; GPCR; PROTEASE; PROTEINASE-ACTIVATED RECEPTOR; THROMBIN;

ANIMALS; HUMANS; INFLAMMATION; RECEPTORS, PROTEINASE-ACTIVATED; SIGNAL TRANSDUCTION;

EID: 84895156496     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12544     Document Type: Review

References (71)

1. Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, et al. (2011). Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther 130: 248-282.
2. Al-Ani B, Saifeddine M, Hollenberg MD, (1995). Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle. Can J Physiol Pharmacol 73: 1203-1207.
3. Al-Ani B, Wijesuriya SJ, Hollenberg MD, (2002). Proteinase-activated receptor 2: differential activation of the receptor by tethered ligand and soluble peptide analogs. J Pharmacol Exp Ther 302: 1046-1054.
4. Al-Ani B, Hansen KK, Hollenberg MD, (2004). Proteinase-activated receptor-2: key role of amino-terminal dipeptide residues of the tethered ligand for receptor activation. Mol Pharmacol 65: 149-156.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al (2013), The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
6. Arizmendi NG, Abel M, Mihara K, Davidson C, Polley D, Nadeem A, et al. (2011). Mucosal allergic sensitization to cockroach allergens is dependent on proteinase activity and proteinase-activated receptor-2 activation. J Immunol 186: 3164-3172.
7. Blackhart BD, Ruslim-Litrus L, Lu CC, Alves VL, Teng W, Scarborough RM, et al. (2000). Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol Pharmacol 58: 1178-1187.
8. Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, et al. (1996). Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J 314 (Pt 3): 1009-1016.
9. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A, (2005). PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 303-313.
10. Burger MM, (1970). Proteolytic enzymes initiating cell division and escape from contact inhibition of growth. Nature 227: 170-171.
11. Carney DH, Cunningham DD, (1977). Initiation of check cell division by trypsin action at the cell surface. Nature 268: 602-606.
12. Carney DH, Cunningham DD, (1978). Transmembrane action of thrombin initiates chick cell division. J Supramol Struct 9: 337-350.
13. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, et al. (2008). Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 51: 3061-3064.
14. Chen LB, Buchanan JM, (1975). Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci U S A 72: 131-135.
15. Chow JM, Moffatt JD, Cocks TM, (2000). Effect of protease-activated receptor (PAR)-1, -2 and -4-activating peptides, thrombin and trypsin in rat isolated airways. Br J Pharmacol 131: 1584-1591.
16. Chrétien M, (2012). My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. Biochem Cell Biol 90: 750-768.
17. Connolly AJ, Ishihara H, Kahn ML, Farese RV, Jr, Coughlin SR, (1996). Role of the thrombin receptor in development and evidence for a second receptor. Nature 381: 516-519.
18. Cuatrecasas P, (1969). Interaction of insulin with the cell membrane: the primary action of insulin. Proc Natl Acad Sci U S A 63: 450-457.
19. Cuatrecasas P, (1971). Properties of the insulin receptor of isolated fat cell membranes. J Biol Chem 246: 7265-7274.
20. Defea K, (2008). Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br J Pharmacol 153 (Suppl. 1): S298-S309.
21. Dulon S, Leduc D, Cottrell GS, D'Alayer J, Hansen KK, Bunnett NW, et al. (2005). Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. Am J Respir Cell Mol Biol 32: 411-419.
22. de Haën C, (1976). The non-stoichiometric floating receptor model for hormone sensitive adenylyl cyclase. J Theor Biol 58: 383-400.
23. Han A, (2008). GB88 is a biased ligand by inhibiting Ca2+ release but inducing ERK and MAPK activation without inducing PAR2 internalisation. Honours thesis, University of Queensland.
24. Hansen KK, Saifeddine M, Hollenberg MD, (2004). Tethered ligand-derived peptides of proteinase-activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells. Immunology 112: 183-190.
25. Hollenberg MD, Laniyonu AA, Saifeddine M, Moore GJ, (1993). Role of the amino- and carboxyl-terminal domains of thrombin receptor-derived polypeptides in biological activity in vascular endothelium and gastric smooth muscle: evidence for receptor subtypes. Mol Pharmacol 43: 921-930.
26. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, et al. (1997). Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386: 502-506.
27. Jacobs S, Cuatrecasas P, (1976). The mobile receptor hypothesis and 'cooperativity' of hormone binding. Application to insulin. Biochim Biophys Acta 433: 482-495.
28. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, et al. (1998). A dual thrombin receptor system for platelet activation. Nature 394: 690-694.
29. Kawabata A, Saifeddine M, Al-Ani B, Leblond L, Hollenberg MD, (1999). Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands. J Pharmacol Exp Ther 288: 358-370.
30. Kenakin T, (2011). Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336: 296-302.
31. Kenakin T, Miller LJ, (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
32. Kinlough-Rathbone RL, Perry DW, Guccione MA, Rand ML, Packham MA, (1993). Degranulation of human platelets by the thrombin receptor peptide SFLLRN: comparison with degranulation by thrombin. Thromb Haemost 70: 1019-1023.
33. Kono T, Barham FW, (1971). Insulin-like effects of trypsin on fat cells. Localization of the metabolic steps and the cellular site affected by the enzyme. J Biol Chem 246: 6204-6209.
34. Lohman RJ, Cotterell AJ, Barry GD, Liu L, Suen JY, Vesey DA, et al. (2012a). An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats. FASEB J 26: 2877-2887.
35. Lohman RJ, Cotterell AJ, Suen JY, Liu L, Do TA, Vesey DA, et al. (2012b). Antagonism of protease activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther 340: 256-265.
36. Maryanoff BE, Zhang HC, Andrade-Gordon P, Derian CK, (2003). Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1). Curr Med Chem Cardiovasc Hematol Agents 1: 13-36.
37. Mihara K, Ramachandran R, Renaux B, Saifeddine M, Hollenberg MD, (2013). Neutrophil elastase and proteinase-3 trigger G-protein biased signaling through proteinase activated receptor-1 (PAR1). J Biol Chem 288: 32979-32990.
38. Mosnier LO, Sinha RK, Burnier L, Bouwens EA, Griffin JH, (2012). Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood 120: 5237-5246.
39. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR, (2000). PAR3 is a cofactor for PAR4 activation by thrombin. Nature 404: 609-613.
40. Nanevicz T, Ishii M, Wang L, Chen M, Chen J, Turck CW, et al. (1995). Mechanisms of thrombin receptor agonist specificity. Chimeric receptors and complementary mutations identify an agonist recognition site. J Biol Chem 270: 21619-21625.
41. Nichols HL, Saffeddine M, Theriot BS, Hegde A, Polley D, El-Mays T, et al. (2012). Beta-arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway. Proc Natl Acad Sci U S A 109: 16660-16665.
42. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J, (1994). Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A 91: 9208-9212.
43. Ostrowska E, Reiser G, (2008). The protease-activated receptor-3 (PAR-3) can signal autonomously to induce interleukin-8 release. Cell Mol Life Sci 65: 970-981.
44. Puente XS, Sanchez LM, Gutierrez-Fernandez A, Velasco G, Lopez-Otin C, (2005). A genomic view of the complexity of mammalian proteolytic systems. Biochem Soc Trans 33 (Pt 2): 331-334.
45. Ramachandran R, (2012). Developing PAR1 antagonists: minding the endothelial gap. Discovery Medicine 13: 425-431.
46. Ramachandran R, Hollenberg MD, (2008). Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 153 (Suppl. 1): S263-S282.
47. Ramachandran R, Mihara K, Mathur M, Rochdi MD, Bouvier M, Defea K, et al. (2009). Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. Mol Pharmacol 76: 791-801.
48. Ramachandran R, Mihara K, Chung H, Renaux B, Lau CS, Defea KA, et al. (2011). Neutrophil elastase acts as a biased agonist for proteinase activated receptor-2 (PAR2). J Biol Chem 286: 24638-24648.
49. Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD, (2012). Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov 11: 69-86.
50. Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger Y, Pages G, Pavirani A, et al. (1991). cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett 288: 123-128.
51. Rasmussen UB, Gachet C, Schlesinger Y, Hanau D, Ohlmann P, Van Obberghen-Schilling E, et al. (1993). A peptide ligand of the human thrombin receptor antagonizes alpha-thrombin and partially activates platelets. J Biol Chem 268: 14322-14328.
52. Rieser P, (1967). The insulin-like action of pepsin and pepsinogen. Acta Endocrinol (Copenh) 54: 375-379.
53. Rieser P, Rieser CH, (1964). Anabolic responses of diaphragm muscle to insulin and to other pancreatic proteins. Proc Soc Exp Biol Med 116: 669-671.
54. Russo A, Soh UJ, Paing MM, Arora P, Trejo J, (2009). Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proc Natl Acad Sci U S A 106: 6393-6397.
55. Schuepbach RA, Feistritzer C, Brass LF, Riewald M, (2008). Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood 111: 2667-2673.
56. Schuepbach RA, Madon J, Ender M, Galli P, Riewald M, (2012). Protease activated receptor-1 cleaved at R46 mediates cytoprotective effects. J Thromb Haemost 10: 1675-1684.
57. Sefton BM, Rubin H, (1970). Release from density dependent growth inhibition by proteolytic enzymes. Nature 227: 843-845.
58. Sevigny LM, Zhang P, Bohm A, Lazarides K, Perides G, Covic L, et al. (2011). Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci U S A 108: 8491-8496.
59. Shoelson SE, White MF, Kahn CR, (1988). Tryptic activation of the insulin receptor. Proteolytic truncation of the alpha-subunit releases the beta-subunit from inhibitory control. J Biol Chem 263: 4852-4860.
60. Steiner DF, (2011). On the discovery of precursor processing. Methods Mol Biol 768: 3-11.
61. Steiner DF, Cunningham D, Spigelman L, Aten B, (1967). Insulin biosynthesis: evidence for a precursor. Science 157: 697-700.
62. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, et al. (2000). Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 6: 151-158.
63. Suen JY, Barry GD, Lohman RJ, Halili MA, Cotterell AJ, Le GT, et al. (2012). Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br J Pharmacol 165: 1413-1423.
64. Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, et al. (2009). Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 137: 332-343.
65. Vergnolle N, Hollenberg MD, Sharkey KA, Wallace JL, (1999). Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol 127: 1083-1090.
66. Vouret-Craviari V, Van Obberghen-Schilling E, Rasmussen UB, Pavirani A, Lecocq JP, Pouyssegur J, (1992). Synthetic alpha-thrombin receptor peptides activate G protein-coupled signaling pathways but are unable to induce mitogenesis. Mol Biol Cell 3: 95-102.
67. Vouret-Craviari V, Van Obberghen-Schilling E, Scimeca JC, Van Obberghen E, Pouyssegur J, (1993). Differential activation of p44mapk (ERK1) by alpha-thrombin and thrombin-receptor peptide agonist. Biochem J 289 (Pt 1): 209-214.
68. Vu TK, Hung DT, Wheaton VI, Coughlin SR, (1991a). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057-1068.
69. Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR, (1991b). Domains specifying thrombin-receptor interaction. Nature 353: 674-677.
70. Werle E, Erdos EG, (1954). [A new hypotensive, enterotropic and hysterotropic substance in human urine.]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 223: 234-243.
71. Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, et al. (1998). Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A 95: 6642-6646.